H.C. Wainwright Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $6
Erasca Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Erasca Analyst Ratings
BofA Securities Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $5
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)
Morgan Stanley Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $4
Morgan Stanley Keeps Their Buy Rating on Erasca (ERAS)
Erasca (ERAS) Gets a Buy From J.P. Morgan
Raymond James Initiates Erasca(ERAS.US) With Buy Rating, Announces Target Price $5
BofA Securities Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $5
Raymond James Initiates Erasca at Outperform With $5 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)
BofA Securities Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Initiates Erasca(ERAS.US) With Buy Rating, Announces Target Price $6
Erasca Price Target Cut to $3.00/Share From $3.50 by Goldman Sachs
Erasca Is Maintained at Buy by Goldman Sachs
Erasca Analyst Ratings
Erasca Analyst Ratings
Morgan Stanley Initiates Erasca(ERAS.US) With Buy Rating, Announces Target Price $4
BofA Securities Maintains Erasca(ERAS.US) With Buy Rating, Maintains Target Price $5